Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.97 USD | +1.51% | -1.60% | -6.46% |
23/05 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
23/05 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.46% | 146.07Cr | |
+15.54% | 7.76TCr | |
+12.05% | 878.09Cr | |
+58.17% | 493.27Cr | |
-14.94% | 479.38Cr | |
0.00% | 380.28Cr | |
+21.94% | 246.13Cr | |
-26.63% | 219.88Cr | |
+16.75% | 210.38Cr | |
-37.97% | 196.44Cr |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024